Oramed Pharmaceuticals Inc.

Regulatory Filings • Aug 4, 2017

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

* 1. Name and Address of Reporting Person Li Xiaopeng					2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP ]									(Check all applicable) X	5. Relationship of Reporting Person(s) to Issuer Director		10% Owner
(Last) (First) (Middle) HAN KOU ROAD, NO. 266, FLOOR 11				3. Date of Earliest Transaction (Month/Day/Year) 08/02/2017										Officer (give title below)	Other (specify below)
(Street) SHANGHAI F4 200001 (City) (State) (Zip)				4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
							Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)				if any		2A. Deemed Execution Date, (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)				Owned	5. Amount of Securities Beneficially	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership
							Code	V	Amount		(A) or (D)	Price		Following Reported Transaction(s) (Instr. 3 and 4)	(Instr. 4)	(Instr. 4)
COMMON STOCK 08/02/2017								P		89,636		A	\$8.5		206,350	D
							Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. 3. Transaction 3A. Deemed Conversion Date Execution Date, or Exercise (Month/Day/Year) if any Price of Derivative		4. Transaction Code (Instr. (Month/Day/Year) 8)			5. Number of Derivative Securities Acquired	Expiration Date (Month/Day/Year)	6. Date Exercisable and	7. Title and Amount of Securities Underlying Derivative			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned	10. Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Disposed of (D) (Instr. 3, 4 and 5) 3 and 4) Reported Transaction(s) (Instr. 4) 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

(A) or

Explanation of Responses:

Security

/s/ Xiaopeng Li 08/03/2017

Security (Instr.

Following

(I) (Instr.

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.